Prosecution Insights
Last updated: August 18, 2026

Kymera Therapeutics Inc.

9 pending office actions • 5 art units • 8 examiners • 0 of 9 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days

Portfolio Summary

9
Total Pending OAs
4
Non-Final OAs
4
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (33%)
3
Medium (33%)
3
Easy (33%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (11%)
§102 only2 (22%)
§112 only3 (33%)
Multi-statute (no §101)3 (33%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

8
Life Sciences
89% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
1
Business / Other
11% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

90 h
Manual time on pending OAs
18 h
Time saved (low, 20%)
31 h
Time saved (mid, 35%)
0.8 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
CHEN, PO-CHIH 2 74.3% +14.4%
ABDALHAMEED, MANAHIL MIRGHANI ALI 1 50.4% +40.1%
GONZALEZ, LUISALBERTO 1 61.2% +44.9%
RAO, SAVITHA M 1 60.6% +30.0%
YOO, SUN JAE 1 71.0% +0.3%
SANCHEZ, JUSTIN CHRISTOPHER 1 86.4% +14.7%
BURKETT, DANIEL JOHN 1 65.2% +30.6%
BRAUN, MADELINE E 1 67.6% +26.4%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17597631 PROTEIN DEGRADERS AND USES THEREOF SANCHEZ, JUSTIN CHRISTOPHER

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18559492 DEUTERATED IRAK DEGRADERS AND USES THEREOF ABDALHAMEED, MANAHIL MIRGHANI ALI 32d overdue
18763437 STAT DEGRADERS AND USES THEREOF CHEN, PO-CHIH
18002116 IRAK DEGRADERS AND USES THEREOF RAO, SAVITHA M

Interview Candidates (8)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17597166 IRAK DEGRADERS AND USES THEREOF BURKETT, DANIEL JOHN 164d overdue
18559492 DEUTERATED IRAK DEGRADERS AND USES THEREOF ABDALHAMEED, MANAHIL MIRGHANI ALI 32d overdue
18763437 STAT DEGRADERS AND USES THEREOF CHEN, PO-CHIH
18453156 CDK2 DEGRADERS AND USES THEREOF GONZALEZ, LUISALBERTO
18002116 IRAK DEGRADERS AND USES THEREOF RAO, SAVITHA M
17597628 FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF CHEN, PO-CHIH
17597631 PROTEIN DEGRADERS AND USES THEREOF SANCHEZ, JUSTIN CHRISTOPHER
17596486 SMARCA DEGRADERS AND USES THEREOF BRAUN, MADELINE E

Top Art Units

Art UnitApps
1622 2
1624 2
1621 2
1691 1
1626 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18763437 STAT DEGRADERS AND USES THEREOF CHEN, PO-CHIH §103§112Other Non-Final OA Pending Jul 03, 2024
18559492 DEUTERATED IRAK DEGRADERS AND USES THEREOF ABDALHAMEED, MANAHIL MIRGHANI ALI 1622 §102§103Other Non-Final OA 32d overdue Pending Nov 07, 2023
18453156 CDK2 DEGRADERS AND USES THEREOF GONZALEZ, LUISALBERTO 1624 §112 Non-Final OA Pending Aug 21, 2023
18002116 IRAK DEGRADERS AND USES THEREOF RAO, SAVITHA M 1691 §102§103 Non-Final OA Pending Dec 16, 2022
17997463 IRAK INHIBITORS AND USES THEREOF YOO, SUN JAE 1621 §102 Non-Final OA Pending Oct 28, 2022
17597628 FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF CHEN, PO-CHIH 1621 §102 Final Rejection Pending Jan 14, 2022
17597631 PROTEIN DEGRADERS AND USES THEREOF SANCHEZ, JUSTIN CHRISTOPHER 1622 §112 Final Rejection Pending Jan 14, 2022
17597166 IRAK DEGRADERS AND USES THEREOF BURKETT, DANIEL JOHN 1624 §103 Final Rejection 164d overdue Pending Dec 28, 2021
17596486 SMARCA DEGRADERS AND USES THEREOF BRAUN, MADELINE E 1626 §112 Final Rejection Pending Dec 10, 2021

Managing Kymera Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month